Roche Diagnostics Operations, Inc.

Boehringer Mannheim Gmbh

Roche Molecular Systems, Inc.

Roche Diagnostics Gmbh

University of Toronto

Boehringer Mannhiem Gmbh

Roche Diabetes Care, Inc.

F. Hoffmann-la Roche Ag

Herbert Von Der Eltz

Frank Bergmann

Frank Seela

Dieter Heindl

Erasmus Huber

Klaus Muhlegger

Rupert Herrmann

Christian Birkner

Christoph Seidel

Gerald F Sigler

Uwe Kobold

Raymond Hui

Ina Deras

Hans-Georg Batz

Thomas Fischer

Axel Schmidt

Walter Eberle

Klaus M&uuml;hlegger

Thomas Duelffer

Georg Hess

Dirk Block

Ursula-Henrike Wienhues-Thelen

Elli Rauscher

Richard Terry Root

Andrew Emili

Hendrik Huedig

Anthony Gramolini

Peter Liu

David MacLennan

Sigrun Metz

Peter Kern

Klaus Muehlegger

Vincent Fong

Ruth Isserlin

Thomas Kislinger

Christian Klein

Hans-Peter Josel

Mitali Ghoshal

Hans Seidel

Hans-Joachim Guder

Erhard Fernholz

Sibylle Berner

Martina Junius

Zigmunt Kasimierczuk

Armin Reidel

Axel Heuser

Helmet Rosemeyer

Herbert Waldman

Heinz-Hartmut Seliger

Georg Becher

David H Gelfand

Joachim Hoenes

Michael Schraeml

Herbert Andres

Otto-Henning Wilhelms

Piet Herdewijn

Mara Boenitz-Dulat

Rainer Schmuck

Peter Sluka

Eva Hoess

Androniki Roesch

Ulrich Neumann

Gregor Sagner

Rudolf Vogel

Michael Grol

Peter Kratzsch

Helmgard Gauhl

Christine Markert-Hahn

Kurt Weindel

Manfred Watzele

Klaus Kaluza

Lili Arabshahi

Frederic Donie

Leopold Von Proff

Bernd Vogt

Peter Stahl

Andreas Gallusser

Matthias Hinzpeter

Ursula Klause

Monika Soukupova

Helmut Rosemeyer

Daniela Beck

Andreas Finke

Bruno Zink

Horst Donner

Heribert Maerz

Ivo Glynne Gut

Wolfgang Jona

Wolfgang Hosel

Rupert Hermann

Anton Haselbeck

Hans-Joachim Hoeltke

Waldemar Adam

Peter Bialk

Rainer Beckert

Werner Naser

Federic Donie

Harald Debelak

Klaus Mühlegger

Haijuan Li

The present disclosure relates to a set of at least 100 single-stranded oligonucleotide probes directed against (or complementary to) portions of a genomic target sequence of interest. The present disclosure also relates to a method of detecting a genomic target sequence of interest using the set of oligonucleotide probes and a method of generating the set of oligonucleotide probes. Further, the present disclosure relates to a kit comprising the set of oligonucleotide probes and at least one further component.

Set of oligonucleotide probes as well as methods and uses thereto

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.

Use of IGFBP-7 in the assessment of heart failure

The present disclosure relates to a set of at least 100 single-stranded oligonucleotide probes directed against (or complementary to) portions of a genomic target sequence of interest. The present disclosure also relates to a method of detecting a genomic target sequence of interest using the set of oligonucleotide probes and a method of generating the set of oligonucleotide probes. Further the present disclosure relates to a kit comprising the set of oligonucleotide probes and at least one further component.

A binding agent of the Formula A-a':a-S-b:b&#x2032;-B:X(n), wherein A as well as B is a monovalent binder, a&#x2032;:a as well as b:b&#x2032; is a binding pair wherein a&#x2032; and a do not interfere with the binding of b to b&#x2032; and vice versa, S is a spacer of at least 1 nm in length, :X denotes a functional moiety bound either covalently or via a binding pair to at least one of a&#x2032;, a, b, b&#x2032; or S, (n) is an integer and at least 1, &#x2014; represents a covalent bond, and the linker a-S-b has a length of 6 to 100 nm. Also disclosed are methods of producing such binding agent and certain uses thereof.

Binding agent

The invention provides a composition containing an aqueous liquid phase, bacterial cells, and an ionic compound dissolved in the liquid phase. The ionic compound is selected from the group consisting of 1-butyl-3-methyl-imidazolium-thiocyanate, 1-butyl-3-methyl-imidazolium-2(2-methoxy-ethoxy)ethylsulfate, 1-methyl-1-[4-(3-methyl-3H-imidazol-1-ium)-but-1-yl]-3H-imidazolium-di(toluylsulfate), and 1-butyl-3-methyl-imidazolium-octylsulfate. The compositions of the invention are advantageously used for preparing lysates of biological cells, particularly bacterial cells.

Reagents for lysis of bacterial cells

The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1.

Use of SLIM-1 in the assessment of heart failure

Disclosed are water-soluble ionic liquids suitable for promoting adsorption of nucleic acids to a solid phase. The use thereof, particularly methods for the isolation of nucleic acids from an aqueous solution, as well as kits for performing those methods are disclosed.

Isolation and purification of nucleic acids with a solid phase

The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and methods for the determination of nucleic acids using said compounds in the field of diagnostics.

Nucleic acid binding compounds containing pyrazolo[3,4-D]pyrimidine analogues of purin-2,6-diamine and their uses

The invention concerns compounds of the general formula (I) in which the residues Rto Rhave the meanings given in the application as well as methods for their preparation. The compounds are in particular suitable as substrates for RNA or DNA polymerases and can thus be incorporated into RNA or DNA oligonucleotides and are especially suitable for labelling and detecting nucleic acids or for DNA sequencing. 

Heterocyclic compounds and their use in the detection of nucleic acids

The present invention relates to a method of measuring a vitamin D metabolite in a sample, the method comprising the steps of (a) treating said sample with a vitamin D metabolite releasing reagent under conditions appropriate to release a vitamin D metabolite from vitamin D-binding protein and not to cause protein precipitation, (b) subjecting the treated sample obtained in step (a) to a chromatographic separation, and (c) measuring a vitamin D metabolite during or after said chromatographic separation. The present invention also relates to methods for determining the vitamin D status of a subject, for use in the diagnosis of disease, and to agents and kits for use in performing the methods of the invention.

Measurement of vitamin D

The invention relates to a method for differentially hemolyzing whole blood. It discloses methods for detecting an analyte in a liquid sample known or suspected to contain red blood cells and suspected or known to contain eukaryotic cells, the method including the steps of processing the liquid sample with a membrane solubilizing agent under conditions appropriate to lyse cell membranes of red blood cells and at the same time not to cause precipitation of sample constituents, subjecting the processed sample to a chromatographic separation, and detecting the analyte. The differential hemolysis of red blood cells is of advantage in a method of detecting an analyte in a liquid sample that may contain both erythrocytes and nucleated cells. The differential solubilization of red blood cells can be easily combined with an online detection methodology, like LC-MS, and is advantageous in the detection of many analytes, e.g. in the detection of folate or of immunosuppressive drugs, like tacrolimus or sirolimus.

Differential hemolysis of a whole blood sample

Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.

Protease inhibitor conjugates and antibodies useful in immunoassay

Growing community of inventors

Weilheim, Germany

Herbert Von Der Eltz